Why the study?
Coronary heart disease and diabetes cause significant cardiovascular burden in India, and the metabolic agent trimetazidine required evaluation on blood parameters in normal and diseased animal models.
Does trimetazidine improve blood parameters in normal, hyperlipidemic, and diabetic rat models?
Does trimetazidine improve blood parameters in normal, hyperlipidemic, and diabetic rat models?
In a preclinical rat model, trimetazidine at 40 mg/kg demonstrated potential beneficial effects against streptozotocin-induced diabetic syndromes.
Should not change practice; leaves open whether TMZ’s glycemic effects in diabetic-hyperlipidemic rats translate to patients with CHD.
The epidemic of cardiovascular disease especially coronary heart disease (CHD) is emerging in rural India and accelerating in urban India. Coronary heart disease is the leading cause of death in India; diabetes accounts for a significant burden of CHD events. Trimetazidine (TMZ) is a piperazine derivative with anti-ischaemic properties. It is the first in a new class of metabolic agent, available for clinical use. : To determine the effect of TMZ on blood parameters in normal, hyperlipidemic, diabetic and Streptozotocin induced diabetic hyperlipidemic rats. Adult male albino rats of Wistar strain, weighing approximately 150 to 180 g, were used in the present study. After various treatments, blood was collected from the rats by sinocular puncture for the blood parameters like Fasting blood glucose, urine sugar, HbA1c and Haemoglobin with standard protocols. The levels of blood glucose, HbA1c and urine sugar were found to be elevated in the entire diseased control group than normal control. TMZ has the potential effect against the STZ induced syndromes with an optimum dose of 40 mg/kg in rats.
No takes yet. Share an insight, caveat, or question.
Preethi et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: